Toggle menu
  • Login or Sign Up
  • 0
    • USD
      • British Pound
      • US Dollar
  • Biopharma Research
    Reset Search ×
    • 0
    Reset Search ×
    • USD
      • British Pound
      • US Dollar

      Main Menu

    • OUR SERVICES
      • Custom Research Services
      • Laboratory End User Surveys
    • ABOUT US
    • CONTACT US
    • Shop By Category

    • All Diagnostics Markets
    • PARTNERING, LICENSING, M&A
    • Multiplex Diagnostics
    • Therapeutics
    • Genomics
    • Cancer Diagnostics
    • Infectious Disease Diagnostics
    • COVID-19 Diagnostics
    • Point of Care (POC) Diagnostics
    • Direct-to-Consumer (DTC) Diagnostics
    • Rapid Diagnostics
    • Laboratory Techniques
    • Medical Laboratory Services
    • Calibration
    • USD
      • British Pound
      • US Dollar
    • Gift Certificates
    • Login or Sign Up

    Market ReportsMarket Reports

    Shop by Category

  • All Diagnostics Markets
  • PARTNERING, LICENSING, M&A
  • Multiplex Diagnostics
  • Therapeutics
  • Genomics
  • Cancer Diagnostics
  • Infectious Disease Diagnostics
  • COVID-19 Diagnostics
  • Point of Care (POC) Diagnostics
  • Direct-to-Consumer (DTC) Diagnostics
  • Rapid Diagnostics
  • Laboratory Techniques
  • Medical Laboratory Services
  • Calibration

    • Main Menu

    • OUR SERVICES
      • Custom Research Services
      • Laboratory End User Surveys
    • ABOUT US
    • CONTACT US
    • Shop By Category

    • All Diagnostics Markets
    • PARTNERING, LICENSING, M&A
    • Multiplex Diagnostics
    • Therapeutics
    • Genomics
    • Cancer Diagnostics
    • Infectious Disease Diagnostics
    • COVID-19 Diagnostics
    • Point of Care (POC) Diagnostics
    • Direct-to-Consumer (DTC) Diagnostics
    • Rapid Diagnostics
    • Laboratory Techniques
    • Medical Laboratory Services
    • Calibration
    Reset Search ×
    • 0
    • Home
    • Therapeutics
    • Global Antibody Partnering Terms and Agreements 2016-2023
  • Top Antibody Deals by Deal Type
  • Global Antibody Partnering Terms and Agreements 2016 to 2023
  • Top Antibody Deals by Deal Type Global Antibody Partnering Terms and Agreements 2016 to 2023

    Global Antibody Partnering Terms and Agreements 2016-2023

    $3,995.00
    (You save )
    Write a Review

    SKU:
    CP2113-SU-1
    Availability:
    Report will be sent the same business day after receipt of cleared payment

    Adding to cart… category.add_cart_announcement

    Share This Article

    • Overview

    Product Description

    Global Antibody Partnering Terms and Agreements 2016-2023

    • Publication date: May 2023
    • Page count: 1100+
    • Format: Interactive PDF and online
    • Edition no: 3

    Request a sample

    The Global Antibody Partnering Terms and Agreements 2016 to 2023 report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

    The report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

    This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

    • Antibodies
    • Antibody-drug conjugates
    • Monoclonal antibodies
      • Murine mAb
      • Chimeric mAb
      • Humanized mAb
      • Human aAb
    • Bispecific antibodies 
    • Polyclonal antibodies

    Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

    This report contains over 1,900 links to online copies of actual antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

    The initial chapters of this report provide an orientation of antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibody dealmaking since 2016, including details of average headline, upfront, milestone and royalty terms.

    Chapter 3 provides a review of the leading antibody deals since 2016. Deals are listed by headline value, signed by big pharma, most active antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

    Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibody dealmaking with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

    Chapter 5 provides a comprehensive and detailed review of antibody partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

    Chapter 6 provides a comprehensive and detailed review of antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

    In addition, a comprehensive appendix is provided organized by antibody partnering company A-Z, deal type definitions and antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

    The report also includes numerous tables and figures that illustrate the trends and activities in antibody partnering and dealmaking since 2016.

    In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibody technologies and products.

     

    Key benefits

    Global Antibody Partnering Terms and Agreements 2016 to 2023 provides the reader with the following key benefits:

    • In-depth understanding of antibody deal trends since 2016
    • Access to headline, upfront, milestone and royalty data
    • Detailed access to actual antibody contracts enter into by the leading 25 bigpharma companies
    • Insight into the terms included in a antibody agreement, together with real world clause examples
    • Understand the key deal terms companies have agreed in previous deals           
    • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

     

    Report scope

     

    Global Antibody Partnering Terms and Agreements 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to antibody trends and structure of deals entered into by leading companies worldwide.

     

    Global Antibody Partnering Terms and Agreements 2016 to 2023 includes:     

    • Trends in antibody dealmaking in the biopharma industry since 2016
    • Access to headline, upfront, milestone and royalty data
    • Access to over 1,900 antibody online deal records
    • The leading antibody deals by value since 2016
    • Most active antibody dealmakers since 2016
    • The leading antibody partnering resources

     

    In Global Antibody Partnering Terms and Agreements 2016 to 2023, the available contracts are listed by:

     

    • Company A-Z
    • Headline value
    • Stage of development at signing
    • Deal component type
    • Specific therapy target

     

    Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

     

    The Global Antibody Partnering Terms and Agreements 2016 to 2023 report provides comprehensive access to available deals and contract documents for over 1,900 antibody deals. Analyzing actual contract agreements allows assessment of the following:

     

    • What are the precise antibody rights granted or optioned?
    • What is actually granted by the agreement to the partner company?
    • What exclusivity is granted?
    • What is the payment structure for the deal?
    • How are sales and payments audited?
    • What is the deal term?
    • How are the key terms of the agreement defined?
    • How are IPRs handled and owned?
    • Who is responsible for commercialization?
    • Who is responsible for development, supply, and manufacture?
    • How is confidentiality and publication managed?
    • How are disputes to be resolved?
    • Under what conditions can the deal be terminated?
    • What happens when there is a change of ownership?
    • What sublicensing and subcontracting provisions have been agreed?
    • Which boilerplate clauses does the company insist upon?
    • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
    • Which jurisdiction does the company insist upon for agreement law?

    Product Videos

    Custom Field

    Product Reviews

    Write a Review

    Write a Review

    ×
    Top Antibody Deals by Deal Type
    Global Antibody Partnering Terms and Agreements 2016-2023
    ×
    • Recommended
    • You May Also Like
    Global Precision Medicine Partnering Terms and Agreements 2016 to 2023 - Deal Trends, Players and Financials Global Precision Medicine Partnering Terms and Agreements 2016 to 2023 - Deal Trends, Players and Financials
    Quick view

    Global Precision Medicine Partnering Terms and Agreements 2016-2023

    $3,995.00 - $9,995.00
    Choose Options
    Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials
    Quick view

    Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials

    $3,995.00 - $9,995.00
    Choose Options
    Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials
    Quick view

    Global Infectious Disease Vaccine Partnering Terms and Agreements 2016-2023

    $3,995.00 - $9,995.00
    Choose Options
    Global Diagnostics Partnering Terms and Agreements 2016 to 2023 Global Diagnostics Partnering Terms and Agreements 2016 to 2023
    Quick view

    Global Diagnostics Partnering Terms and Agreements 2016-2023

    $3,995.00 - $9,995.00
    Choose Options
    Companion Diagnostics (CDx) Partnering by Deal Type Global Companion Diagnostics (CDx) Partnering Terms and Agreements 2010 to 2023
    Quick view

    Global Companion Diagnostics Partnering Terms and Agreements 2010-2023

    $3,995.00 - $9,995.00
    Choose Options
    Companion Diagnostics (CDx) Partnering by Deal Type Global Companion Diagnostics (CDx) Partnering Terms and Agreements 2010 to 2023
    Quick view

    Global Companion Diagnostics Partnering Terms and Agreements 2010-2023

    $3,995.00 - $9,995.00
    Choose Options
    Global Precision Medicine Partnering Terms and Agreements 2016 to 2023 - Deal Trends, Players and Financials Global Precision Medicine Partnering Terms and Agreements 2016 to 2023 - Deal Trends, Players and Financials
    Quick view

    Global Precision Medicine Partnering Terms and Agreements 2016-2023

    $3,995.00 - $9,995.00
    Choose Options
    Global Diagnostics Partnering Terms and Agreements 2016 to 2023 Global Diagnostics Partnering Terms and Agreements 2016 to 2023
    Quick view

    Global Diagnostics Partnering Terms and Agreements 2016-2023

    $3,995.00 - $9,995.00
    Choose Options
    Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials
    Quick view

    Global Infectious Disease Vaccine Partnering Terms and Agreements 2016-2023

    $3,995.00 - $9,995.00
    Choose Options
    Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials
    Quick view

    Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials

    $3,995.00 - $9,995.00
    Choose Options
    Cancer Immunotherapy Markets 2023 to 2027
    Quick view

    Cancer Immunotherapy Markets - The Race for the Cures: Forecasts for Immuno-Oncology Therapeutics by Cancer, Therapy and Customer with Executive and Consultant Guides 2023 to 2027

    $6,995.00 - $13,995.00
    Choose Options
    Metagenomic Markets 2023 to 2027
    Quick view

    Metagenomics Markets: Global Market Analysis with Forecasts by Applications, Technologies, Product and User with Executive and Consultant Guides 2023 to 2027

    $6,995.00 - $13,995.00
    Choose Options
    Latent TB Diagnostics Markets 2023 to 2027
    Quick view

    Latent TB Diagnostics: Global Market Analysis and Forecasts by Assay, Risk Factor and Lab/Place with Executive and Consultant Guides 2023 to 2027

    $6,995.00 - $13,995.00
    Choose Options
    Smart In Vitro Diagnostics Markets 2023 to 2027
    Quick view

    SMART IN VITRO DIAGNOSTICS: ARTIFICIAL INTELLIGENCE FOR IVD MARKETS BY APPLICATION, TECHNOLOGY AND USER WITH EXECUTIVE AND CONSULTANT GUIDES 2023-2027

    $6,995.00 - $13,995.00
    Choose Options
    Antibiotic Resistance Markets (Therapeutics) 2023 to 2027
    Quick view

    Antibiotic Resistance Markets (Therapeutics): Market Insights and Forecasts by Pathogen and Therapy with Situation Analysis, Executive and Investment Guides 2023 to 2027

    $6,995.00 - $13,995.00
    Choose Options
    • You May Also Like
    • Recommended
    • Companion Diagnostics (CDx) Partnering by Deal Type Global Companion Diagnostics (CDx) Partnering Terms and Agreements 2010 to 2023
      Quick view

      Global Companion Diagnostics Partnering Terms and Agreements 2010-2023

      $3,995.00 - $9,995.00
      Choose Options
    • Global Precision Medicine Partnering Terms and Agreements 2016 to 2023 - Deal Trends, Players and Financials Global Precision Medicine Partnering Terms and Agreements 2016 to 2023 - Deal Trends, Players and Financials
      Quick view

      Global Precision Medicine Partnering Terms and Agreements 2016-2023

      $3,995.00 - $9,995.00
      Choose Options
    • Global Diagnostics Partnering Terms and Agreements 2016 to 2023 Global Diagnostics Partnering Terms and Agreements 2016 to 2023
      Quick view

      Global Diagnostics Partnering Terms and Agreements 2016-2023

      $3,995.00 - $9,995.00
      Choose Options
    • Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials
      Quick view

      Global Infectious Disease Vaccine Partnering Terms and Agreements 2016-2023

      $3,995.00 - $9,995.00
      Choose Options
    • Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials
      Quick view

      Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials

      $3,995.00 - $9,995.00
      Choose Options
    • Cancer Immunotherapy Markets 2023 to 2027
      Quick view

      Cancer Immunotherapy Markets - The Race for the Cures: Forecasts for Immuno-Oncology Therapeutics by Cancer, Therapy and Customer with Executive and Consultant Guides 2023 to 2027

      $6,995.00 - $13,995.00
      Choose Options
    • Metagenomic Markets 2023 to 2027
      Quick view

      Metagenomics Markets: Global Market Analysis with Forecasts by Applications, Technologies, Product and User with Executive and Consultant Guides 2023 to 2027

      $6,995.00 - $13,995.00
      Choose Options
    • Latent TB Diagnostics Markets 2023 to 2027
      Quick view

      Latent TB Diagnostics: Global Market Analysis and Forecasts by Assay, Risk Factor and Lab/Place with Executive and Consultant Guides 2023 to 2027

      $6,995.00 - $13,995.00
      Choose Options
    • Smart In Vitro Diagnostics Markets 2023 to 2027
      Quick view

      SMART IN VITRO DIAGNOSTICS: ARTIFICIAL INTELLIGENCE FOR IVD MARKETS BY APPLICATION, TECHNOLOGY AND USER WITH EXECUTIVE AND CONSULTANT GUIDES 2023-2027

      $6,995.00 - $13,995.00
      Choose Options
    • Antibiotic Resistance Markets (Therapeutics) 2023 to 2027
      Quick view

      Antibiotic Resistance Markets (Therapeutics): Market Insights and Forecasts by Pathogen and Therapy with Situation Analysis, Executive and Investment Guides 2023 to 2027

      $6,995.00 - $13,995.00
      Choose Options
    • Global Precision Medicine Partnering Terms and Agreements 2016 to 2023 - Deal Trends, Players and Financials Global Precision Medicine Partnering Terms and Agreements 2016 to 2023 - Deal Trends, Players and Financials
      Quick view

      Global Precision Medicine Partnering Terms and Agreements 2016-2023

      $3,995.00 - $9,995.00
      Choose Options
    • Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials
      Quick view

      Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials

      $3,995.00 - $9,995.00
      Choose Options
    • Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials
      Quick view

      Global Infectious Disease Vaccine Partnering Terms and Agreements 2016-2023

      $3,995.00 - $9,995.00
      Choose Options
    • Global Diagnostics Partnering Terms and Agreements 2016 to 2023 Global Diagnostics Partnering Terms and Agreements 2016 to 2023
      Quick view

      Global Diagnostics Partnering Terms and Agreements 2016-2023

      $3,995.00 - $9,995.00
      Choose Options
    • Companion Diagnostics (CDx) Partnering by Deal Type Global Companion Diagnostics (CDx) Partnering Terms and Agreements 2010 to 2023
      Quick view

      Global Companion Diagnostics Partnering Terms and Agreements 2010-2023

      $3,995.00 - $9,995.00
      Choose Options
    ×
    Contact Us
    Westfield House
    Millfield Lane
    Nether Poppleton
    YORK, YO26 6GA
    United Kingdom
    +44(0)1904 868857
    Accounts & Orders
    • Login or Sign Up
    • Order Status
    • Privacy Security Shipping
    Navigate
    • OUR SERVICES
    • ABOUT US
    • CONTACT US
    Join Our Mailing List

    Sign up for our newsletter to receive specials and up to date product news and releases.

    • © Biopharma Research Ltd